137 related articles for article (PubMed ID: 21447007)
1. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis.
Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
Eur J Haematol; 2011 Jul; 87(1):54-60. PubMed ID: 21447007
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance.
Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Res; 2012 Nov; 36(11):1387-92. PubMed ID: 22877729
[TBL] [Abstract][Full Text] [Related]
3. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.
Skov V; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC; Larsen TS
Exp Hematol; 2012 Sep; 40(9):771-780.e19. PubMed ID: 22659388
[TBL] [Abstract][Full Text] [Related]
5. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2012 Jan; 53(1):123-9. PubMed ID: 21806350
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation.
Hasselbalch HC; Skov V; Stauffer Larsen T; Thomassen M; Hasselbalch Riley C; Jensen MK; Bjerrum OW; Kruse TA
PLoS One; 2014; 9(1):e85567. PubMed ID: 24454890
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
8. Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis.
Skov V; Riley CH; Thomassen M; Larsen TS; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2013 Oct; 54(10):2269-73. PubMed ID: 23302045
[TBL] [Abstract][Full Text] [Related]
9. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
10. High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis.
Hasselbalch HC; Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA
Leuk Res; 2011 Oct; 35(10):1330-4. PubMed ID: 21470677
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression profile in granulocytes from primary myelofibrosis patients.
Guglielmelli P; Tozzi L; Pancrazzi A; Bogani C; Antonioli E; Ponziani V; Poli G; Zini R; Ferrari S; Manfredini R; Bosi A; Vannucchi AM;
Exp Hematol; 2007 Nov; 35(11):1708-18. PubMed ID: 17976522
[TBL] [Abstract][Full Text] [Related]
12. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.
Skov V; Riley CH; Thomassen M; Kjær L; Stauffer Larsen T; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2017 Aug; 58(8):1914-1921. PubMed ID: 27911124
[TBL] [Abstract][Full Text] [Related]
13. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
Hasselbalch HC
Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
[TBL] [Abstract][Full Text] [Related]
14. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
15. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).
Guglielmelli P; Zini R; Bogani C; Salati S; Pancrazzi A; Bianchi E; Mannelli F; Ferrari S; Le Bousse-Kerdilès MC; Bosi A; Barosi G; Migliaccio AR; Manfredini R; Vannucchi AM
Stem Cells; 2007 Jan; 25(1):165-73. PubMed ID: 16990584
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
Muth M; Engelhardt BM; Kröger N; Hussein K; Schlué J; Büsche G; Kreipe HH; Bock O
Ann Hematol; 2011 Jan; 90(1):33-40. PubMed ID: 20625903
[TBL] [Abstract][Full Text] [Related]
18. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
19. Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis.
Bock O; Muth M; Theophile K; Winter M; Hussein K; Büsche G; Kröger N; Kreipe H
Br J Haematol; 2009 Sep; 146(5):510-20. PubMed ID: 19604240
[TBL] [Abstract][Full Text] [Related]
20. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
